HealthDay News — For patients with advanced unresectable hepatocellular carcinoma (HCC), the effect of sorafenib on overall survival (OS) is dependent on patients’ hepatitis status, according to a meta-analysis published in the Journal of Clinical Oncology.
Richard Jackson, from the Liverpool Cancer Trials Unit in the United Kingdom, and colleagues undertook an individual patient data meta-analysis of 3 prospective randomized trials in which sorafenib was the control arm. Data were included for 1643 patients with advanced unresectable HCC who received sorafenib.
The researchers found that patients who were both hepatitis B virus (HBV) negative and hepatitis C virus (HCV) positive had improved OS for sorafenib (log [hazard ratio], −0.27). In this subgroup, the median unadjusted survival was 12.6 and 10.2 months for sorafenib and other treatments, respectively. Other patient subgroups defined by HBV and HCV did not have improvement in OS. Consistent results were seen across all trials.
“There is consistent evidence that the effect of sorafenib on OS is dependent on patients’ hepatitis status,” the authors write. “There is an improved OS for patients negative for HBV and positive for HCV when treated with sorafenib.”
One author disclosed financial ties to the pharmaceutical industry; Bristol-Myers Squibb, Pfizer, and AbbVie gave access to data from studies in which they acted as sponsor.
Jackson R, Psarelli EE, Berhane S, Khan H, Johnson P. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trials [published online January 3, 2017]. J Clin Oncol. doi: 10.1200/JCO.2016.69.5197